17,261 trials
Renal Cancer
Primary: Number of Participants With Adverse Events Associated With Vaccination With Mature DC/Tumor Fusion and GM-CSF — 12 participants
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Cutaneous T-cell Lymphoma · Mycosis Fungoides · Sezary Syndrome
Primary: Number of Participants With a 50% Improvement in Baseline Skin Score — 0 participants
Bladder, Neurogenic
Primary: Percentage of LPP Responders for Group D-Denovo and Group D-527.51 Rollover — 73.1; 35.7; 26.7; 67.9 percentage of responders
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 — 29.0; 30.3; 27.4; 39.1 percentage…
Pain · Phlebotomy · Palliative Care
Primary: Percentage of Patients With No or Minor Pain (VAS<3) — 38.0; 21.3 percentage of participants
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Primary: Coefficient of Fat Absorption (CFA) — 71.0; 70.9; 71.8; 75.9 percentage of fat intake
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20 Response Based on C-reactive Protein (ACR20-CRP) at Week 26 — 46.1; 44.9; 57.7; 70.9 percentage…
Influenza Infection
Primary: Number of Participants Reporting Solicited Local and Systemic Adverse Events (AEs) — 7; 5; 4; 0 participants
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
Cancer
Primary: Time-to-progression (TTP) — 5 months
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Objective Response Rate at Weeks 17 and 25 — 20; 14; 22; 14 percentage of participants
Osteoarthritis, Knee
Primary: Change From Baseline in the International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score at 1 Year — 23.3; 9.9 scores on a scale — p=<0.01
Meningitis · Meningococcemia
Primary: Percentage of Participants With Serum Meningococcal Serogroups A, C, Y, and W-135 Bactericidal Antibody Titers ≥ 1:4 and ≥ 1:8 Before and Following Vaccination With…
HIV Infections
Primary: Area Under the Plasma Concentration Time Curve (AUC) From 0-12 Hours for Enfuvirtide and Its Metabolite (Ro 50-6343) — 56.1; 52.7; 3.07; 3.41 microgram hour per…